Tendyne, the mitral valve replacement technology that Abbott Laboratories Inc. acquired three years ago, has potential to successfully treat patients with severe mitral regurgitation, according to early follow-up data presented May 23 at EuroPCR in Paris.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?